New long-acting HIV drug lenacapavir faces global supply shortages

A new HIV-prevention drug called lenacapavir shows promising results by providing nearly complete protection from HIV with just two injections per year, according to PBS NewsHour and the Associated Press.

Lenacapavir is particularly important for populations such as sex workers in Uganda, who face challenges with condom use and adherence to daily pills or frequent injections of other PrEP medications.

Despite its potential to significantly impact the global HIV epidemic, lenacapavir is in short supply in Uganda, other parts of Africa, and worldwide, limiting access for those who could benefit most.

U.S. regulators have approved a generic version of lenacapavir for sale in low-income countries, but the rollout is not progressing quickly enough to meet demand, as reported by PBS NewsHour.

Health experts emphasize that lenacapavir's long-lasting effects could help change the course of the HIV epidemic, but scaling up production and distribution remains a critical challenge.